The expert faculty discuss the emerging role of circulating tumor DNA (ctDNA) and urinary tumor DNA (utDNA) as biomarkers in bladder cancer, exploring their prognostic and potentially predictive ...

Early treatment intensification with ADT and ARPIs is now standard for mCSPC, with patient-specific factors guiding therapy selection. Enzalutamide, apalutamide, abiraterone, and darolutamide are key ...

Gepotidacin is now approved for treating uncomplicated urogenital gonorrhea in patients 12 years and older, expanding its previous approval for urinary tract infections. The EAGLE-1 trial showed ...

The Revi System, an implantable tibial neuromodulation device, received FDA 510(k) clearance for its enhanced version, improving urgency urinary incontinence treatment. The OASIS trial confirmed the ...

The FDA approved niraparib with abiraterone acetate and prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer based on the AMPLITUDE trial results. The trial demonstrated ...

Experts recommend removing unsupported prostate cancer warnings from TRT labels and aligning indications with professional guidelines. Testosterone's Schedule III classification creates barriers to ...

IsoPSA, a blood-based test, aids in diagnosing high-grade prostate cancer by analyzing PSA protein structural variants. FDA approval was based on a large-scale, prospective study and other validation ...

"Based on the code description, we recommend basing the code selection on the documentation and the effort required to complete the service, and not the number of foreign bodies removed from the ...

Individualized hormone therapy duration for prostate cancer can reduce unnecessary treatment and side effects, based on cancer risk. Meta-analysis of 10,266 men showed diminishing benefits of ADT ...

Fosfomycin received FDA approval for complicated urinary tract infections, demonstrating noninferiority to piperacillin/tazobactam in the ZEUS trial. The FDA removed ...

"The addition of perioperative durvalumab to neoadjuvant chemotherapy significantly improved event-free survival and overall survival without adversely affecting patient-reported outcomes,” said ...